---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-133773"
form_type: "8-K"
ticker: "XLO"
cik: "0001840233"
company_name: "Xilio Therapeutics, Inc."
filed_at: "2025-06-03T23:59:59+00:00"
generated_at: "2026-05-20T01:52:38.685520+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Xilio Therapeutics prices $50M public offering of warrants; cash runway through Q3 2026

## Summary
- Net proceeds of ~$46.6M from offering of pre-funded warrants and Series A/B/C warrants, priced at $0.7499 per unit.
- Cash runway extended to Q3 2026, assuming no contributions from AbbVie or Gilead partnerships.
- Series A warrants exercisable after Dec 1, 2025 or if stock closes above $1.50 for five days; $0.75 exercise price.
- Series B and C warrants subject to offset/cancellation if non-dilutive capital ≥$20M received before Dec 1, 2026.
- If all Series B and C warrants exercised for cash, additional gross proceeds up to ~$100M.

## SEC filing metadata
- accession: 0001193125-25-133773
- form_type: 8-K
- ticker: XLO
- cik: 0001840233
- company_name: Xilio Therapeutics, Inc.
- filed_at: 2025-06-03T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840233/000119312525133773/0001193125-25-133773-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840233/000119312525133773/d88500d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-133773
- JSON: https://secwatch.observer/filing/0001193125-25-133773.json
- Plain text: https://secwatch.observer/filing/0001193125-25-133773.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.